Avidity Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 253
- Market Cap
- $5.1B
- Introduction
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.
Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
- Conditions
- FSHDFSHD1FSHD2FMDFMD2Fascioscapulohumeral Muscular DystrophyFascioscapulohumeral Muscular Dystrophy Type 1Fascioscapulohumeral Muscular Dystrophy Type 2Dystrophies, Facioscapulohumeral MuscularDystrophy, Facioscapulohumeral Muscular
- Interventions
- Drug: AOC 1020
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Avidity Biosciences, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT06547216
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇺🇸University of Washington, Seattle, Washington, United States
Global Study of Del-desiran for the Treatment of DM1
- Conditions
- Myotonic Dystrophy 1Myotonic DisordersDM1Myotonic DystrophySteinertDystrophy MyotonicSteinert DiseaseMyotonic Muscular DystrophyMyotoniaMyotonic Dystrophy Type 1 (DM1)
- Interventions
- Drug: AOC 1001 (del-desiran)Drug: Placebo
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Avidity Biosciences, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06411288
- Locations
- 🇺🇸
University of California, Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸University of California, San Diego (UCSD), San Diego, California, United States
🇺🇸Stanford University, Stanford, California, United States
Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping
- Conditions
- DMDDuchenne Muscular DystrophyDuchenneExon 44
- Interventions
- Drug: AOC 1044
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Avidity Biosciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06244082
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸University of California, San Diego, Rady's Children's Hospital, La Jolla, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
- Conditions
- FSHDFSHD1FSHD2FMDFMD2Fascioscapulohumeral Muscular DystrophyFascioscapulohumeral Muscular Dystrophy Type 1Fascioscapulohumeral Muscular Dystrophy Type 2Dystrophies, Facioscapulohumeral MuscularDystrophy, Facioscapulohumeral Muscular
- Interventions
- Drug: AOC 1020Drug: Placebo
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Avidity Biosciences, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05747924
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸University of California San Diego, San Diego, California, United States
Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping
- Conditions
- Duchenne Muscular DystrophyExon 44
- Interventions
- Drug: PlaceboDrug: AOC 1044
- First Posted Date
- 2023-01-04
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Avidity Biosciences, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05670730
- Locations
- 🇺🇸
Arkansas Children's, Little Rock, Arkansas, United States
🇺🇸UCSD, La Jolla, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
- Conditions
- Musculoskeletal DiseasesDM1Myotonic DystrophyMuscular Disorders, AtrophicMuscular DystrophiesMyotonic DisordersGenetic Diseases, InbornMuscular DiseasesMyotonic Dystrophy 1Neuromuscular Diseases
- Interventions
- Drug: AOC 1001Drug: Placebo
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Avidity Biosciences, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT05479981
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
- Conditions
- Dystrophy MyotonicMyotonic DisordersDM1Steinert DiseaseMyotonic Dystrophy 1Myotonic Muscular DystrophyMyotonic Dystrophy Type 1 (DM1)Myotonic Dystrophy
- Interventions
- Drug: PlaceboDrug: AOC 1001
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Avidity Biosciences, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT05027269
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Kansas University Medical Center, Kansas City, Kansas, United States